Efficacy, durability, and safety of faricimab▼ in diabetic macular edema: 2-year results from the phase 3 YOSEMITE and RHINE trials
This presentation describes 2-year results from the phase 3 YOSEMITE and RHINE trials of faricimab▼ , a dual angiopoietin-2 and VEGF-A pathway inhibitor, in patients with diabetic macular edema. YOSEMITE and RHINE compared the efficacy, safety, and durability of intravitreal faricimab▼ , administered every 8 weeks or per personalized treatment interval up to every 16 weeks, with intravitreal aflibercept administered every 8 weeks.